Associated Papers
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia.
Gutierrez-Camino A et al.
British Journal of Cancer, 2024
Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy.
Ge SS et al.
British Journal of Haematology, 2023
Utility of plasma cell-free DNA for de novo detection and quantification of clonal hematopoiesis.
Gutierrez-Rodrigues F et al.
Haematologica, 2022
34587721 (PubMed )
Supplement: 2021_279230_GUTIERREZ-RODRIGUES_SUPPL.pdf
Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification.
Liu T et al.
Nature Communications, 2022
35347147 (PubMed )
Supplement: 41467_2022_29336_MOESM8_ESM.xlsx › Sheet1
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001.
Tran TH et al.
Blood Advances, 2022
34933343 (PubMed )
Supplement: advancesADV2021005634-suppl1.xlsx › S3_Mutation_details
The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.
Tran TH et al.
Haematologica, 2021
Genetic profile of naïve untreated primary cutaneous melanomas with a negative sentinel lymph node.
Yang K et al.
Clinical and Experimental Dermatology, 2020
Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance.
Patel RK et al.
Plos One, 2019
Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Staudt D et al.
International Journal of Molecular Sciences, 2018
Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease.
Marjanovic I et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2016
Leukemogenic potency of the novel FLT3-N676K mutant.
Huang K et al.
Annals of Hematology, 2016
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.
Smith CC et al.
Cancer Discovery, 2015
Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.
Opatz S et al.
Blood, 2013
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N et al.
Cancer Research, 2009
Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
Cools J et al.
Cancer Research, 2004
Select a paper to view details